Flexible dosing of tincture of opium in the management of opioid withdrawal: pharmacokinetics and pharmacodynamics.
暂无分享,去创建一个
[1] S. Donn,et al. Management of neonatal abstinence syndrome in neonatal intensive care units: a national survey , 2006, Journal of Perinatology.
[2] M. Hellmich,et al. Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. , 2005, Drug and alcohol dependence.
[3] A. Somogyi,et al. Comparison of tincture of opium and methadone to control opioid withdrawal in a Thai treatment centre. , 2004, British journal of clinical pharmacology.
[4] Crime.. WHO/UNODC/UNAIDS position paper. Substitution maintenance therapy in the management of opioid dependence and HIV/AIDS prevention. , 2004 .
[5] L. Antonilli,et al. High levels of morphine-6-glucuronide in street heroin addicts , 2003, Psychopharmacology.
[6] L. Lagasse,et al. Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. , 2002, The Journal of pediatrics.
[7] Jason M. White,et al. Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine , 2001, Pain.
[8] M. Kreek,et al. Methadone‐Related Opioid Agonist Pharmacotherapy for Heroin Addiction: History, Recent Molecular and Neurochemical Research and Future in Mainstream Medicine , 2000, Annals of the New York Academy of Sciences.
[9] A. Somogyi,et al. Steady‐state pharmacokinetics and pharmacodynamics in methadone maintenance patients: Comparison of those who do and do not experience withdrawal and concentration‐effect relationships , 1999, Clinical pharmacology and therapeutics.
[10] Jeff Ward,et al. Role of maintenance treatment in opioid dependence , 1999, The Lancet.
[11] L. Marsch. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. , 1998, Addiction.
[12] A. Somogyi,et al. Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice inpatients. , 1997, Journal of pain and symptom management.
[13] J. Bell,et al. Methadone maintenance and drug-related crime. , 1997, Journal of substance abuse.
[14] M. Gastpar,et al. Pharmacokinetic and pharmacodynamic interactions in an outpatient maintenance therapy of intravenous heroin users with levomethadone , 1996, Addiction biology.
[15] T. Hedner,et al. Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration , 1995, Pain.
[16] D Westerling,et al. Plasma Concentrations of Morphine, Morphine‐3‐Glucuronide, and Morphine‐6‐Glucuronide After Intravenous and Oral Administration to Healthy Volunteers: Relationship to Nonanalgesic Actions , 1995, Therapeutic drug monitoring.
[17] J. Tignol,et al. A naturalistic follow-up study of French-speaking opiate-maintained heroin-addicted patients: effect on biopsychosocial status. , 1994, Journal of substance abuse treatment.
[18] P. Stolley,et al. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. , 1993, Journal of acquired immune deficiency syndromes.
[19] A. Somogyi,et al. Plasma Concentrations and Renal Clearance of Morphine, Morphine-3-Glucuronide and Morphine-6-Glucuronide in Cancer Patients Receiving Morphine , 1993, Clinical pharmacokinetics.
[20] A. Somogyi,et al. High-performance liquid chromatographic determination of morphine and its 3- and 6-glucuronide metabolites: improvements to the method and application to stability studies. , 1991, Journal of chromatography.
[21] L. Öhlund,et al. Mortality in heroin addiction: impact of methadone treatment , 1990, Acta psychiatrica Scandinavica.
[22] J. Svensson,et al. Morphine metabolism in cancer patients on increasing oral doses--no evidence for autoinduction or dose-dependence. , 1983, British journal of clinical pharmacology.
[23] C. B. Christensen,et al. Plasma morphine concentrations during chronic oral administration in patients with cancer pain , 1982, PAIN.
[24] E. Änggård,et al. Methadone maintenance: Plasma levels and therapeutic outcome , 1978, Clinical pharmacology and therapeutics.